Rush Reintroduces Bill Requiring Drug Companies to Properly Label Products that Present an Increased Risk of Suicide or Depression

Sep 19, 2019
Press Release

WASHINGTON — Today, U.S. Representative Bobby L. Rush (D-Ill.) reintroduced an important piece of legislation that would require drug companies to properly label products that present an increased risk of suicide or depression as a side effect.

The Depression Effect Labeling Awareness Act of 2019 (H.R. 4404) was originally introduced last year by Rep. Rush and would amend the Federal Food, Drug, and Cosmetic Act to require that the label of drugs with an increased risk of suicide or depression present such increased risk prominently.

“When Americans are prescribed or buy a drug over-the-counter, they have the right to know what side effects are associated with that drug, particularly if those side effects include an increased risk of depression and/or suicide.

“This bill would ensure that drugs with serious side effects are properly labeled and that all Americans are more informed when it comes to the medications that they are consuming.”

A paper published last summer by the Journal of the American Medical Association showed that prescription medications are increasingly used among adults in the United States and many have a potential for causing depression.